{"id":"NCT05029622","sponsor":"Ipsen","briefTitle":"A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.","officialTitle":"A Phase III, Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Chinese Paediatric Participants With Central Precocious Puberty.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-08-10","primaryCompletion":"2022-08-21","completion":"2023-02-13","firstPosted":"2021-08-31","resultsPosted":"2024-05-28","lastUpdate":"2025-02-19"},"enrollment":66,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Central Precocious Puberty"],"interventions":[{"type":"DRUG","name":"Triptorelin Pamoate","otherNames":[]}],"arms":[{"label":"Triptorelin formulation for Intramuscular injection (IM).","type":"EXPERIMENTAL"}],"summary":"The purpose of the protocol is to assess the efficacy of the triptorelin 6 month PR (Prolonged Release) formulation in suppressing LH (Luteinising hormone) levels to prepubertal levels (defined as a peak LH â‰¤5 IU/L) after i.v. GnRH (Gonadotropin-releasing Hormone) stimulation at Month 6 (Day 169) in Chinese children with CPP (Central Precocious Puberty).","primaryOutcome":{"measure":"Percentage of Participants With Luteinising Hormone (LH) Suppression","timeFrame":"At Month 6","effectByArm":[{"arm":"All Participants","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":4},"locations":{"siteCount":14,"countries":["China"]},"refs":{"pmids":["39412628"],"seeAlso":["https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/08/08212539/D-CN-52014-244-lay-results-summary-1.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":66},"commonTop":["Upper respiratory tract infection","COVID-19","Pyrexia","Weight increased","Cough"]}}